Nathan Y. Tat
Research Subjects
Nathan Y. Tat has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chien-Te Kent Tseng
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
2 shared publications - George Golovko
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, USA
2 shared publications - Kamil Khanipov
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA
2 shared publications - Pinghan Huang
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA
2 shared publications - Vivian Y. Tat
Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, USA
2 shared publications - Candise Tat
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital, Houston, Texas
1 shared publication
Latest Publications
- Open Access
Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.
Open AccessEvaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.
- Open Access
- 23 May 2024
- Published by MDPI AG in Preprints.org
Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity score-matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1-30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.
- 23 May 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity score-matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1-30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.
- 23 October 2023
- Published by Journal of Science Policy and Governance, Inc. in Journal of Science Policy & Governance
- Vol. 23 (1)
The US Space Program's Path Forward for Low-Earth Orbit (LEO) after Decommissioning of the International Space Station (ISS)
As activities in space rapidly evolve, the International Space Station (ISS) is approaching its retirement date. Since decommissioning of the ISS is scheduled for 2030, the United States (US) must identify paths forward for space station operations in low-earth orbit (LEO). Having a manned LEO space station after the conclusion of the ISS program will allow the US to continue possessing a platform to conduct scientific research, advance technology, and investigate the effects of microgravity on biological physiology. Options to continue LEO operations include having private entities construct and operate commercial space stations, reusing components of the ISS, directing NASA to spearhead efforts in building a new space station, or abandoning US-led space stations in LEO altogether. We recommend that commercial firms build and operate space stations, permitting multiple platforms to be created while maintaining the legacy of the ISS. The US will have facilities in LEO for research and development, thus advancing technological and scientific knowledge for Earth-based applications and future space missions.
- 23 October 2023
- Published by Journal of Science Policy and Governance, Inc. in Journal of Science Policy & Governance
- Vol. 23 (1)
The US Space Program's Path Forward for Low-Earth Orbit (LEO) after Decommissioning of the International Space Station (ISS)
As activities in space rapidly evolve, the International Space Station (ISS) is approaching its retirement date. Since decommissioning of the ISS is scheduled for 2030, the United States (US) must identify paths forward for space station operations in low-earth orbit (LEO). Having a manned LEO space station after the conclusion of the ISS program will allow the US to continue possessing a platform to conduct scientific research, advance technology, and investigate the effects of microgravity on biological physiology. Options to continue LEO operations include having private entities construct and operate commercial space stations, reusing components of the ISS, directing NASA to spearhead efforts in building a new space station, or abandoning US-led space stations in LEO altogether. We recommend that commercial firms build and operate space stations, permitting multiple platforms to be created while maintaining the legacy of the ISS. The US will have facilities in LEO for research and development, thus advancing technological and scientific knowledge for Earth-based applications and future space missions.